Published in J Exp Med on June 01, 1985
Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci U S A (1985) 1.01
Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity. Neoplasia (2010) 0.81
Changes in leucocyte populations following murine bifunctional antibody infusion in colon cancer patients. Clin Exp Immunol (1991) 0.78
Murine monoclonal anti-idiotope antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys. Proc Natl Acad Sci U S A (1992) 0.78
Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry (1978) 22.56
In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol (1981) 3.34
Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci U S A (1982) 2.21
On the heterogeneity of murine natural killer cells. J Exp Med (1981) 2.15
IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci U S A (1982) 2.15
The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function. J Immunol (1979) 2.11
The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect. J Immunol (1979) 2.02
In vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature (1981) 1.71
Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res (1980) 1.70
Natural killer cells may be the only cells in normal mouse lymphoid cell populations endowed with cytolytic ability for antibody-coated tumour target cells. Scand J Immunol (1978) 1.58
Antigenic profile of murine natural killer cells. J Immunol (1980) 1.51
Bone marrow graft rejection as a function of antibody-directed natural killer cells. J Exp Med (1985) 1.35
Heterogeneity of natural killer cells in the mouse. J Exp Med (1981) 1.25
Therapy of mouse lymphoma with monoclonal antibodies to glycolipid: selection of low antigenic variants in vivo. Science (1981) 1.21
Tumor necrosis serum induces a serologically distinct population of NK cells. J Exp Med (1979) 1.15
Normal levels of natural cytotoxic cells against solid tumours in NK-deficient beige mice. Nature (1981) 1.12
Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc Natl Acad Sci U S A (1983) 1.12
Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo. Proc Natl Acad Sci U S A (1983) 1.10
Natural cytotoxic cells against solid tumors in mice. III. A comparison of effector cell antigenic phenotype and target cell recognition structures with those of NK cells. J Immunol (1981) 1.05
Evidence that natural cytotoxicity and antibody-dependent cellular cytotoxicity are mediated in humans by the same effector cell populations. J Immunol (1979) 1.00
Prevention of rejection of allogeneic bone marrow transplants by NK 1.1 antiserum. Transplantation (1983) 0.99
In vivo reduction of NK activity with anti-NK 1 serum: direct evaluation of NK cells in tumor clearance. Int J Cancer (1982) 0.96
Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system. Cancer Res (1982) 0.94
Correlation between natural and antibody-dependent cell-mediated cytotoxicity against tumor targets in the mouse. I. Distribution of the reactivity. J Natl Cancer Inst (1979) 0.85
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 9.51
A procedure for rapid and sensitive staining of protein fractionated by polyacrylamide gel electrophoresis. Anal Biochem (1967) 7.96
Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition. Proc Natl Acad Sci U S A (1983) 4.56
Protein iodination with solid state lactoperoxidase. Biochemistry (1974) 4.52
Electrophoretic heterogeneity of polypeptide chains of specific antibodies. Science (1966) 3.88
Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo. J Exp Med (1985) 3.48
Culture supernatants of a stimulated T-cell line have helper activity that acts synergistically with interleukin 2 in the response of B cells to antigen. Proc Natl Acad Sci U S A (1981) 3.28
Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. Clin Immunol Immunopathol (1975) 3.11
Polarization of the Golgi apparatus and the microtubule-organizing center within cloned natural killer cells bound to their targets. Proc Natl Acad Sci U S A (1983) 2.85
Cytolysis by H-2-specific T killer cells. Assembly of tubular complexes on target membranes. J Exp Med (1983) 2.78
Assembly of two types of tubules with putative cytolytic function by cloned natural killer cells. Nature (1983) 2.62
Effects of oleate starvation in a fatty acid auxotroph of Escherichia coli K-12. J Bacteriol (1969) 2.53
Cytotoxic T cells learn specificity for self H-2 during differentiation in the thymus. Nature (1978) 2.51
Effects of cytotoxic monoclonal antibody specific for T200 glycoprotein on functional lymphoid cell populations. Cell Immunol (1980) 2.47
Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci U S A (1994) 2.30
Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol (1998) 2.28
Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci U S A (1982) 2.21
Octreotide therapy for tumor-induced osteomalacia. N Engl J Med (2001) 2.19
Salt extraction of soluble HL-A antigens. Science (1971) 2.18
Reorientation of the microtubule-organizing center and the Golgi apparatus in cloned cytotoxic lymphocytes triggered by binding to lysable target cells. J Immunol (1984) 2.09
Separation of 7S gamma-1-globulin, 7S gamma-2-globulin and macroglobulin guinea pig antibodies. Proc Soc Exp Biol Med (1966) 2.08
Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A (1992) 2.07
Translation of the structural genes of the E. coli pyruvate dehydrogenase complex. Cold Spring Harb Symp Quant Biol (1966) 2.06
Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res (1984) 2.01
Serologic evidence for antigens controlled by the Ir region in mice. J Exp Med (1973) 1.94
Evidence for non-identity of T killer and T helper cells sensitised to allogeneic cell antigens. Nature (1974) 1.89
Structural studies of murine I-E and human DR antigens. Mol Immunol (1979) 1.79
Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. Proc Natl Acad Sci U S A (1996) 1.78
Induction of B cell differentiation by T cell factors. I. Stimulation of IgM secretion by products of a T cell hybridoma and a T cell line. J Immunol (1981) 1.73
The Lyt phenotype of a long-term allospecific T cell line. Both helper and killer activities to IA are mediated by Ly-1 cells. Eur J Immunol (1981) 1.72
Transplantation antigens. Adv Immunol (1970) 1.70
Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A (1978) 1.70
Selective priming of T cells by chemically altered cell antigens. J Exp Med (1972) 1.69
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res (1990) 1.69
Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer (2011) 1.69
Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res (1987) 1.68
Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol (1998) 1.67
Continuously proliferating allospecific T cells, lifespan and antigen receptors. Eur J Immunol (1977) 1.65
Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst (1997) 1.64
Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood (1998) 1.64
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer (1997) 1.63
The reorientation of the Golgi apparatus and the microtubule-organizing center in the cytotoxic effector cell is a prerequisite in the lysis of bound target cells. J Mol Cell Immunol (1985) 1.62
Domain closure in adenylate kinase. Joints on either side of two helices close like neighboring fingers. J Mol Biol (1993) 1.61
Stimulation of humoral antibody formation by polyanions. I. The effect of polyacrylic acid on the primary immune response in mice immunized with sheep red blood cells. Eur J Immunol (1971) 1.61
NK cells cause liver injury and facilitate the induction of T cell-mediated immunity to a viral liver infection. J Immunol (2000) 1.60
A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer (1995) 1.59
The mechanism of antibody-induced stimulation and inhibition of the immune response. J Immunol (1971) 1.58
Phagocytic cells as effectors in a cell-mediated immunity system. J Immunol (1973) 1.56
A rapid method for direct HL-A typing of cultured lymphoid cells. J Immunol (1971) 1.55
Altered patterns of cerebral activity during speech and language production in developmental stuttering. An H2(15)O positron emission tomography study. Brain (1997) 1.54
Individual cow's milk allergens as prognostic markers for tolerance development? Clin Exp Allergy (2012) 1.54
Continuously proliferating allospecific T cells. I. Specificity of cooperation with allogeneic B cells in the humoral antibody response to sheep erythrocytes. J Exp Med (1979) 1.54
Stimulation of humoral antibody formation by polyanions. II. The influence of sulfate esters of polymers on the immune response in mice. Eur J Immunol (1971) 1.52
Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci U S A (1992) 1.51
Characterization of Ia antigens in mouse serum. J Immunol (1976) 1.51
Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J Cell Biol (1996) 1.50
Cloned cell lines with natural killer activity. Specificity, function, and cell surface markers. J Exp Med (1981) 1.49
Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res (1991) 1.48
Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res (1984) 1.48
Cell interactions in humoral and cell-mediated immunity. Nat New Biol (1972) 1.47
Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res (1989) 1.45
An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in an divalent cation-dependent functional complex with the disialoganglioside GD2. J Cell Biol (1987) 1.44
Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol (1990) 1.44
A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother (1992) 1.44
Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma (1981) 1.42
Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci U S A (1984) 1.39
O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science (1984) 1.38
T cells may express multiple activities: specific allohelp, cytolysis, and delayed-type hypersensitivity are expressed by a cloned T-cell line. Proc Natl Acad Sci U S A (1981) 1.37
Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res (1994) 1.36
Effects of a cloned cell line with NK activity on bone marrow transplants, tumour development and metastasis in vivo. Nature (1982) 1.35
Continuously proliferating T killer cells specific for H-2b targets: selection and characterization. J Immunol (1976) 1.35
Bone marrow graft rejection as a function of antibody-directed natural killer cells. J Exp Med (1985) 1.35
Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res (1998) 1.33
A novel cell type responsible for marrow graft rejection in mice. T cells with NK phenotype cause acute rejection of marrow grafts. J Immunol (1989) 1.32
Isolation and characterization of a mitogen from pokeweek (Phytolacca americana). Proc Natl Acad Sci U S A (1967) 1.32
Cloned lines of natural killer cells. Nature (1980) 1.32
Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci (1997) 1.31
A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside. J Biol Chem (1984) 1.31
Effect of substituted benzimidazoles on acid secretion in isolated and enriched guinea pig parietal cells. Gut (1983) 1.29
Polyanions and lipopolysaccharide acts on different subpopulations of B cells. Nature (1974) 1.28
Effects of retinoic acid on the immune system: stimulation of T killer cell induction. Eur J Immunol (1978) 1.28
Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol (1997) 1.27
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res (1997) 1.27
KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol (1998) 1.26
Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity (2001) 1.26
Are contact hypersensitivity cells cytotoxic? Nature (1975) 1.26
Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci U S A (1996) 1.25
Analysis of a novel linkage unit of O-linked carbohydrates from the crystalline surface layer glycoprotein of Clostridium thermohydrosulfuricum S102-70. J Bacteriol (1992) 1.25
Evidence for extrathymic development of TNK cells. NK1+ CD3+ cells responsible for acute marrow graft rejection are present in thymus-deficient mice. J Immunol (1992) 1.23
Tyrosine-incorporating amber suppressors in Escherichia coli K12. J Mol Biol (1968) 1.23
Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res (1997) 1.22
Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans. J Biol Chem (1984) 1.22
Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res (1991) 1.22
Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res (1998) 1.21